Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
10 nov. 2022 16h05 HE
|
Vincerx Pharma, Inc.
Received Orphan Drug Designation for enitociclib; continue to focus on priority indications IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 expected by year-end IND...
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022
03 nov. 2022 09h05 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
11 août 2022 16h05 HE
|
Vincerx Pharma, Inc.
Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND...
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
10 juin 2022 08h00 HE
|
Vincerx Pharma, Inc.
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity,...
Vincerx Pharma Provides Key Strategic Update
06 juin 2022 16h05 HE
|
Vincerx Pharma, Inc.
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND filings for VIP236 in 2H22 and for VIP943 in...
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update
12 mai 2022 16h05 HE
|
Vincerx Pharma, Inc.
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual...
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022
08 avr. 2022 13h05 HE
|
Vincerx Pharma, Inc.
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic...
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
29 mars 2022 08h00 HE
|
Vincerx Pharma, Inc.
Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in...
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
08 mars 2022 16h35 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
09 févr. 2022 08h00 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...